| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant full-length human protein was used as the immunogen for the MED22 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
MED22 Antibody is an antibody targeting MED22. Host: Mouse. Monoclonal. Clone: PCRP-MED22-1E4. Format: Purified. Applications: ELISA, IF, FACS, WB.
Key elements and design rationale
- Target: MED22.
- Immunogen: Recombinant full-length human protein was used as the immunogen for the MED22 antibody..
- Species reactivity: Human.
- Localization: Nucleus.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Med22 is a subunit of the RNA polymerase II (Pol II) transcriptional mediator complex. The mediator complex is a coactivator involved in the regulated transcription of Pol II-dependent genes.
Common research applications
- WB: relative abundance and band pattern assessment using appropriate controls.
- IF/ICC: subcellular localization imaging with proper background controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
